Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. (KMDA) is a leading biopharmaceutical company that specializes in plasma-derived protein therapeutics, targeting orphan indications. Utilizing its proprietary platform technology, Kamada excels in the extraction and purification of proteins from human plasma, producing highly-purified, liquid forms of alpha-1 antitrypsin (AAT) and other plasma-derived proteins. AAT is recognized for its immunomodulatory, anti-inflammatory, tissue-protective, and antimicrobial properties.
One of Kamada's flagship products is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration (FDA). Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada offers a diverse product portfolio, including nine other pharmaceutical products distributed globally.
Kamada's robust late-stage product pipeline underscores its commitment to innovation in the specialty therapeutics market. The company operates through two primary segments: the Proprietary Products segment and the Distribution segment, with the majority of revenue derived from the Proprietary Products segment. Kamada's product categories encompass lung diseases, vaccines, hemophilia, immunoglobulins, critical care, and diagnostics.
Recently, Kamada announced a significant development in its strategic partnership with Kedrion Biopharma. The companies have executed a binding memorandum of understanding for an 8-year extension of the KEDRAB® US distribution agreement, starting January 2024. This agreement includes potential expansion of Kedrion's distribution of KEDRAB® beyond the U.S. and collaboration on expanding Kedrion products' distribution in Israel.
KEDRAB® is a Human Rabies Immune Globulin (HRIG) used for passive, transient post-exposure prophylaxis (PEP) of rabies infection, approved by the FDA in August 2017. The agreement signifies a significant milestone for Kamada, maximizing the future growth and value potential of this important product. Kamada continues to prioritize patient care and remains a pivotal player in the plasma-derived therapies sector.
Kamada Ltd. (NASDAQ: KMDA) has announced a significant transition in its GLASSIA manufacturing process. Kamada will transfer the U.S. Biologics License Application (BLA) to Takeda by the end of 2021, receiving a $2 million payment for the transfer. Additionally, a final $5 million sales-based milestone payment from Takeda was accelerated. Despite this shift, Kamada will continue marketing GLASSIA outside Takeda's territories while investing in the development of an inhaled AAT product, currently in a Phase III clinical trial. Revenue forecasts include approximately $25 million from GLASSIA sales in 2021.
Kamada Ltd. (NASDAQ: KMDA) announced positive results from its Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived hyperimmune globulin treatment for COVID-19. Out of 12 patients, 11 recovered, with 7 discharged by Day 5. The treatment showed no infusion-related reactions, and IgG levels increased significantly, enhancing virus neutralization. The company continues supplying its IgG product to the Israeli Ministry of Health for COVID-19 patients, anticipating $3.4 million in revenue from the initial order to treat 500 patients. Manufacturing is ramping up for potential international demand.
Kamada Ltd. (NASDAQ: KMDA) announced that CEO Amir London will present a corporate overview at the Jefferies Virtual Global Plasma Summit on March 11, 2021, at 9:35 a.m. ET. The presentation will be accessible via a live webcast, with a replay available for 30 days post-event. Kamada specializes in plasma-derived biopharmaceuticals, featuring products like GLASSIA and KEDRAB. The company aims to drive growth from its product lines and ongoing clinical trials, including treatments for COVID-19 and AAT deficiency.
Kamada Ltd. (Nasdaq: KMDA) has completed the acquisition of an FDA-licensed plasma collection center from Blood and Plasma Research, Inc. for approximately $1.66 million. This strategic move aims to enhance Kamada's goal of becoming a fully integrated specialty plasma company. The company plans to expand the hyperimmune plasma collection capacity and leverage the newly acquired FDA license to open additional centers in the U.S. This acquisition marks a significant step towards growing Kamada’s hyperimmune IgG portfolio.
Kamada Ltd. (NASDAQ: KMDA) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC. The report includes audited consolidated financial statements, accessible on the SEC's website and Kamada's investor relations site. Kamada specializes in plasma-derived biopharmaceuticals with a focus on orphan indications. Their leading product, GLASSIA®, is the first liquid AAT product approved by the FDA. Kamada also has a late-stage product pipeline, including inhaled AAT formulations and a new hyperimmune immunoglobulin for COVID-19 treatment.
Kamada Ltd. (NASDAQ: KMDA) reported full-year 2020 revenues of $133.2 million, aligning with guidance and marking a 5% increase from 2019. The company overcame operational challenges from the COVID-19 pandemic, achieving adjusted EBITDA of $25.1 million. Kamada has entered the U.S. plasma collection market through the acquisition of an FDA-approved facility, aiming to expand its hyperimmune IgG portfolio. Additionally, it is supplying a plasma-derived COVID-19 product to the Israeli Ministry of Health, expecting about $3.4 million in related revenue.
Kamada Ltd. (NASDAQ: KMDA), a plasma-derived biopharmaceutical company, will release its financial results for Q4 and fiscal year 2020 on February 10, 2021, before U.S. market open. A conference call will follow at 8:00 AM ET for discussion and Q&A. Kamada is known for its proprietary plasma-derived products, including GLASSIA® and KamRab®, both FDA-approved. The company has late-stage developments, including an inhaled AAT formulation and treatments for COVID-19. FIMI Opportunity Fund is the largest shareholder, owning about 21% of shares.
Kamada Ltd. (Nasdaq: KMDA) has announced its acquisition of Blood and Plasma Research, Inc., located in Beaumont, TX, for approximately $1.63 million. This acquisition marks Kamada's entry into the U.S. plasma collection market and aims to expand its collection capacity of hyper-immune plasma essential for manufacturing the Anti-D immunoglobulin. Kamada plans to enhance its operations by leveraging B&PR’s FDA license to open more centers in the U.S. The deal is projected to close within this quarter, subject to specific conditions.
Kamada Ltd. (NASDAQ: KMDA) has signed an agreement with the Israeli Ministry of Health to supply its investigational anti-SARS-CoV-2 hyperimmune immunoglobulin product for COVID-19 treatment. This initial order will treat around 500 patients and is projected to generate roughly $3.4 million in revenue during Q1 2021. Positive interim results from an ongoing Phase 1/2 trial show favorable safety and symptom improvement in non-ventilated COVID-19 patients. U.S. clinical development is anticipated to commence in early 2021, pending IND acceptance.
Kamada Ltd. (NASDAQ: KMDA) announced it expects to receive approximately $25 million in revenue from the sale of GLASSIA® to Takeda in 2021, which represents Takeda's minimum commitment for that year. The total revenue guidance for Kamada for the full year 2020 remains $132 million to $137 million.
Future royalty payments from Takeda are projected to range from $10 million to $20 million annually from 2022 to 2040. Kamada is preparing to adjust its manufacturing plans in light of these developments and is exploring additional business opportunities to enhance future growth.
FAQ
What is the current stock price of Kamada (KMDA)?
What is the market cap of Kamada (KMDA)?
What does Kamada Ltd. specialize in?
What is Kamada's flagship product?
Who are Kamada's strategic partners?
What are the main product categories of Kamada?
What recent agreement has Kamada announced?
What is KEDRAB®?
How does Kamada derive its majority of revenue?
What are the key properties of alpha-1 antitrypsin (AAT)?
Which markets does Kamada distribute its pharmaceutical products?
What is the significance of Kamada's recent agreement with Kedrion Biopharma?
